Lua Labs Report — Melatonin-progesterone: the nocturnal signal that connects sleep, the luteal phase, and fertility

Date: 2026-06-12 Researcher: Lua Labs Classification: Chronobiology Line: L4 — Hormonal chronobiology Subtopic: 4.2 — Melatonin-progesterone: the sleep-fertility connection and its deterioration in perimenopause

External sources

1. Greendale GA, Witt-Enderby PA, Karlamangla AS, et al. (2020). "Melatonin Patterns and Levels During the Human Menstrual Cycle and After Menopause." Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvaa115
2. Taketani T, Tamura H, Takasaki A, et al. (2011). "Protective role of melatonin in progesterone production by human luteal cells." Journal of Pineal Research. https://doi.org/10.1111/j.1600-079X.2011.00878.x
3. Sadeghpour S, Rashtian J, Abdi N, Malekahmadi S, Esfandiari S, Borumandnia N, Ghahremani-Nasab M, Bakhtiyari M. (2025). "The effects of melatonin on follicular oxidative stress and assisted reproductive outcomes in women with diminished ovarian reserve: a double-blind randomized controlled trial." European Journal of Obstetrics & Gynecology and Reproductive Biology. https://doi.org/10.1016/j.ejogrb.2025.09.029
4. Wu C, Huang J. (2025). "Effects of melatonin as an adjuvant treatment on assisted reproductive outcomes in infertile women: a systematic review and meta-analysis." Frontiers in Reproductive Health. https://doi.org/10.3389/frph.2025.1680984
5. Hu X, Yin C, Yang Y, et al. (2026). "From nighttime light exposure to menstrual health: a review of light-at-night disruptions on circadian rhythm and reproductive hormones." Frontiers in Reproductive Health. https://doi.org/10.3389/frph.2026.1738574
6. Ogawa S, et al. (2025). "Effects of Hormone Replacement Therapy on Sleep Apnea and Sleep-Related Parameters in Perimenopausal and Postmenopausal Women." Journal of Menopausal Medicine. https://doi.org/10.6118/jmm.24030
7. Hosenfeld CS, Herson PS, Spencer RL. (2025). "Progesterone and Sleep: A Preclinical Review." Endocrinology. https://doi.org/10.1210/endocr/bqaf047

Baseline knowledge (what I know before searching)

Melatonin is not just a "sleep hormone." It is the endocrine darkness signal of the circadian system. The pathway begins in the retina, especially intrinsically photosensitive ganglion cells with melanopsin, which project to the suprachiasmatic nucleus. When light falls, the SCN permits sympathetic output toward the pineal gland through the paraventricular nucleus, intermediolateral column, and superior cervical ganglion. Pineal norepinephrine activates melatonin synthesis from serotonin through AANAT and ASMT. Nighttime light, especially blue-enriched light, interrupts this output and reduces melatonin amplitude even when a person "sleeps enough hours."

In the ovary, melatonin operates through two pathways that matter for Lua Labs. First, as a timing signal through MT1/MT2 (MTNR1A/MTNR1B), G-protein-coupled receptors that modulate cAMP, calcium, and intracellular signaling. Second, as a local antioxidant molecule: the follicle and corpus luteum are tissues with high steroidogenesis, high mitochondrial activity, and high exposure to reactive oxygen species. Producing progesterone requires moving cholesterol into the mitochondrion through StAR, converting it to pregnenolone through CYP11A1, and then to progesterone through HSD3B. That machinery is vulnerable to oxidative stress, inflammation, glucocorticoids, and circadian desynchrony.

Progesterone and melatonin push the night in complementary but tense directions. Progesterone is thermogenic: after ovulation it raises basal temperature, probably through hypothalamic action and changes in heat-dissipation thresholds. Melatonin favors sleep and a nocturnal drop in core temperature, partly by facilitating distal vasodilation. A healthy luteal phase is not isolated "high progesterone"; it is a choreography: enough darkness for melatonin, a competent corpus luteum for progesterone, neurosteroid conversion to allopregnanolone, and enough nocturnal heat dissipation to sustain sleep.

Allopregnanolone is the neuroendocrine bridge that turns the luteal phase into subjective experience. Progesterone is reduced by 5-alpha-reductase (SRD5A1/SRD5A2) to 5-alpha-dihydroprogesterone and then by 3-alpha-hydroxysteroid dehydrogenases (AKR1C family) to allopregnanolone. It positively modulates GABA-A receptors. In many women it may promote sleep continuity and lower excitability; in others, especially with PMDD-like sensitivity, rapid changes in allopregnanolone and GABA-A subunit plasticity may produce anxiety, irritability, or paradoxical insomnia. This point is central: the same progesterone can feel like calm or activation, depending on circadian, thermal, inflammatory, and genetic context.

Findings from recent papers

Greendale et al. showed in the SWAN study that the melatonin signal is not flat across the cycle. In premenopausal women, the nocturnal urinary metabolite 6-sulfatoxymelatonin peaked around cycle day 17, compatible with the periovulatory/early luteal window. In postmenopause, levels were approximately 1.28 times lower than in premenopause, and the pattern approached that of older adult men. This suggests that the ovary-melatonin axis is bidirectional or at least co-regulated: ovarian state does not only respond to the clock, it also appears to modulate nocturnal amplitude.

Taketani et al. provide the cellular mechanism that makes the melatonin-progesterone connection plausible: in human luteal cells, melatonin protects progesterone production against oxidative stress. This is not a cosmetic effect; if the corpus luteum depends on mitochondria and StAR/CYP11A1/HSD3B, then oxidative damage can turn apparent ovulation into a functionally weak luteal phase. The RCT by Sadeghpour et al. in women with diminished ovarian reserve reinforces this axis in humans: melatonin intervention significantly reduced follicular ROS and improved embryo/fertilization markers, although it did not show a clear improvement in final outcomes such as pregnancy or implantation. The correct reading is not "melatonin increases fertility"; it is that melatonergic signaling touches the reproductive oxidative microenvironment.

The review and meta-analysis by Wu and Huang synthesizes trials in assisted reproduction and finds improvements in clinical/biochemical pregnancy rates, oocytes, and high-quality embryos, with evidence still insufficient or inconclusive for live births. Hu et al. update the environmental side: nighttime light and screens in bed can alter melatonin, sleep, and reproductive hormones, although the field still mixes observational studies, circadian mechanisms, and exposure proxies. Ogawa et al., in perimenopause/postmenopause, show that modifying the hormonal environment with estradiol and progesterone changed apnea/sleep indices in a 6-month pilot; this is not a therapeutic recommendation, but it confirms that the progesterone-sleep axis remains physiologically active during the menopausal transition.

Full molecular/endocrine mechanism

The nocturnal signal relevant to L4.2 can be expressed as a chain of synchrony. If the darkness link fails, the body can preserve "hours in bed" but lose the endocrine signal that prepares the ovary, endometrium, and brain for a stable luteal night.

Real darkness
  ↓
Low retinal melanopsin → SCN releases nocturnal output → PVN/IML/SCG
  ↓
Pineal: tryptophan → serotonin → AANAT → N-acetylserotonin → ASMT → melatonin
  ↓
MT1/MT2 + mitochondrial antioxidant in follicle/corpus luteum
  ↓
Less local ROS + better mitochondrial function
  ↓
Cholesterol → StAR → CYP11A1 → pregnenolone → HSD3B → progesterone
  ↓
Endometrial PR-A/PR-B + hypothalamic thermogenesis + substrate for allopregnanolone
  ↓
SRD5A1/2 → 5-alpha-DHP → AKR1C/3-alpha-HSD → allopregnanolone
  ↓
GABA-A → sleep continuity, lower excitability, anxiety modulation

The typical failure does not need to be an absolute hormone deficiency. It can be a phase loss. In L4.1 we proposed ovarian circadian coherence phenotype because the ovary requires CLOCK/BMAL1 to enable steroidogenesis in specific windows. L4.2 adds that the luteal phase needs a sufficiently coherent nocturnal signal to sustain progesterone, convert part of that progesterone into neurosteroids, and permit a nocturnal thermal curve compatible with sleep.

Nighttime light / screens / late dinner / stress
  ↓
Low or delayed melatonin + shifted SCN
  ↓
Lower follicular/luteal antioxidant protection + relatively high nocturnal cortisol
  ↓
Vulnerable StAR/CYP11A1/HSD3B + less stable corpus luteum
  ↓
Erratic progesterone or short luteal phase
  ↓
Fluctuating allopregnanolone + unstable GABA-A
  ↓
Luteal insomnia, awakenings, nocturnal anxiety, irritability, lower recovery
                                         ↓
                              circadian synchrony, luteal physiology, thyroid-autoimmune context and progesterobolome

Perimenopausal deterioration probably amplifies this chain through three simultaneous inputs. First, follicular reserve and ovulatory quality become more variable; progesterone falls before average estradiol. Second, circadian and melatonergic amplitude tends to decline with age/menopause. Third, vasomotor symptoms, sympathetic activation, nocturnal anxiety, and temperature changes fragment sleep. A woman may perceive this as "I sleep but do not recover" or "my cycle wakes me up," but the underlying phenomenon could be a loss of coupling among darkness, corpus luteum, neurosteroids, and thermoregulation.

Cross-synthesis with previous findings

• L4.1 — ovarian circadian coherence phenotype and LCI: L4.1 established that CLOCK/BMAL1 enable ovarian steroidogenesis through StAR/CYP11A1/HSD3B/CYP19A1/LHCGR/PTGS2. L4.2 turns that architecture into a concrete signal: nocturnal melatonin could be the "darkness input" that protects luteal machinery from oxidative stress and keeps the luteal phase in correct biological time.
• L1 — progesterobolome: L1.2 proposed that gut bacteria can contribute progesterone/allopregnanolone-like metabolites from biliary steroids. L4.2 adds a temporal modulator: that neurosteroid buffer would only have a stable effect if it occurs within a night with sufficient melatonergic signaling. This opens an unexplored synergy: a darkness-dependent gut-neurosteroid axis.
• diurnal cortisol phenotype/metabolic-reproductive phenotype/circadian metabolic-reproductive misalignment: The most fertile window should not be modeled only by calendar or LH. It should include circadian competence: if the nocturnal signal falls, an ovulatory window can exist mechanically but have lower luteal quality, lower endometrial receptivity, and worse recovery.

Lua Labs hypotheses

Hypothesis 32: Luteal melatonin-progesterone synchrony

Statement: Luteal-phase quality and the sleep experience do not depend only on absolute progesterone level, but on the degree of synchrony among nocturnal melatonin signaling, luteal thermal shift, and neurosteroid stability.

Proposed mechanism: High and well-phased nocturnal melatonin reduces follicular/luteal oxidative stress, protects progesterone production, and allows progesterone to exert its thermal and neurosteroid effects in a night physiologically prepared for sleep. If melatonin is delayed or depressed, progesterone may still rise, but it does so over a system with higher sympathetic activation, worse heat dissipation, and greater GABA-A sensitivity. The result is not "progesterone deficiency" but progesterone-darkness desynchrony.

Phased melatonin + high ovarian circadian coherence phenotype
  ↓
Corpus luteum with lower ROS + stable StAR/CYP11A1/HSD3B
  ↓
Stable luteal progesterone
  ↓
Allopregnanolone/GABA-A + compatible nocturnal thermal curve
  ↓
Continuous sleep + lower irritability + better receptivity signal

Confidence level: Medium. The melatonin-ROS-corpus luteum chain has mechanistic support and trials in assisted fertility; synchrony as a composite physiological phenotype is an original proposal pending validation.

How to validate:

• With a formal study: observational cohort with nocturnal 6-sulfatoxymelatonin measurement, salivary/serum progesterone on luteal days, continuous temperature, wearable sleep, and daily symptoms. Minimum design: n=80-120, 2-3 cycles, stratified by regular cycles vs intense luteal symptoms.

Limitations: The weak point is inferring melatonin without measuring it. Sleep and temperature are proxies, not hormones. In addition, hormonal contraceptives, night shifts, primary insomnia, alcohol, apnea, thyroid disease, and PCOS can alter the pattern.

Hypothesis 33: Perimenopausal Dark Signal Collapse

Statement: In early perimenopause, part of the nocturnal symptom burden appears through collapse of the darkness signal before estradiol falls sustainably: lower-amplitude melatonin + intermittent ovulation/progesterone + vasomotor activation fragment sleep and generate a phenotype of "absent progesterone" even if the initial problem is synchrony.

Proposed mechanism: The perimenopausal transition is not a linear ovarian shutdown. It is a period of high variability: anovulatory cycles, short luteal phases, estradiol peaks not compensated by progesterone, and greater autonomic instability. If lower melatonin amplitude with age is added to this, the brain loses a robust signal to organize sleep, temperature, and recovery. The woman can enter a loop: awakenings → more nocturnal cortisol/sympathetic tone → lower sleep quality → greater vasomotor sensitivity → further deterioration of the nocturnal signal.

Confidence level: Medium-high for the components; medium for causal order. There is solid evidence for sleep and hormone changes in perimenopause, but "darkness signal collapse" as an early event requires longitudinal validation.

How to validate:

• With a formal study: perimenopausal cohort with actigraphy/wearable, melatonin metabolite, luteal progesterone, estradiol, FSH, hot-flash diary, and sleep diary. Compare women with still-regular cycles vs early transition.

Limitations: Perimenopause mixes many causes: apnea, weight gain, stress, alcohol, anxiety, medication, hypothyroidism/Hashimoto, and social changes. Fine stratification is needed to avoid overattributing everything to melatonin.

Hypothesis 34: ALLO thermogating

Statement: Allopregnanolone stabilizes luteal sleep only when the night allows heat dissipation and sufficient melatonin; if progesterone raises temperature while melatonin signaling is suppressed, the same progesterone-allopregnanolone pathway can become symptomatic and produce "wired-tired" luteal insomnia.

Proposed mechanism: Progesterone raises basal temperature; melatonin facilitates nocturnal architecture and a drop in core temperature. Allopregnanolone modulates GABA-A, but GABA-A sensitivity depends on context and recent neurosteroid history. In women with high sensitivity, abrupt changes in allopregnanolone on a hot, fragmented, or low-melatonin night could produce paradoxical activation. This would explain why some women feel sedated in the luteal phase and others feel anxious/insomniac in the same hormonal window.

Confidence level: Low-medium. The biology of progesterone, allopregnanolone, and sleep is plausible; "thermogating" as a switch is an original hypothesis and requires direct evidence.

How to validate:

• With a formal study: wearable + serial steroid metabolomics (progesterone, allopregnanolone if available), premenstrual sensitivity questionnaires, distal/core temperature, and urinary melatonin.

Limitations: Allopregnanolone is not measured routinely and its effects are nonlinear. Symptoms may come from pain, digestion, migraine, histamine, thyroid, or apnea. This hypothesis should be treated as a candidate mechanism, not a diagnosis.

Candidate formulation (if applicable)

No pharmacological formulation or individual-use intervention is proposed. The proposal is limited to a research framework for studying melatonin-progesterone synchrony in cohorts with hormonal, sleep, and temperature measurements.

Individual variability

The same melatonin-progesterone signal can have different effects because of genetics, hormonal stage, and inflammatory context. Variants in MTNR1A/MTNR1B could modulate melatonin sensitivity; variants in circadian genes such as CLOCK, BMAL1/ARNTL, PER3, CRY1/2 can change chronotype and response to nighttime light. In steroidogenesis, StAR, CYP11A1, HSD3B, LHCGR affect luteal competence. In neurosteroids, SRD5A1/SRD5A2 and AKR1C can change conversion to allopregnanolone. In GABAergic response, GABA-A subunit composition can determine whether allopregnanolone is experienced as calm or irritability.

Metabolic context also matters. PCOS can alter ovulation, insulin, and the melatonin-reproductive axis. Autoimmune thyroiditis can add fatigue, inflammation, and altered basal temperature. Chronic stress changes GR/FKBP5 signaling and raises nocturnal activation. Alcohol and a late dinner can fragment sleep and raise nocturnal temperature. Perimenopause adds ovulatory variability, greater vasomotor burden, and declining circadian amplitude. The useful question, then, is not "which hormone is low?" but which woman, in which phase, and with which nocturnal signal metabolizes this same hormone differently.